Compounds > 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-enyl)piperazine
Page last updated: 2024-09-20

1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-enyl)piperazine

Cross-References

ID SourceID
PubMed CID3378
CHEMBL ID3195822

Synonyms (36)

Synonym
CBIOL_001758
KBIO1_000043
DIVK1C_000043
SPECTRUM_001208
OPREA1_381078
BIO1_001022
BIO2_000541
BIO1_000533
BIO1_000044
BIO2_000061
KBIO2_004256
KBIOSS_001688
KBIOSS_000061
KBIO2_002629
KBIO2_000061
KBIO3_000121
KBIO2_005197
KBIOGR_000061
KBIO2_006824
KBIOGR_001373
KBIO3_002316
KBIO2_001688
KBIO3_000122
NINDS_000043
SPECTRUM4_000827
PRESTWICK1_000312
SPECTRUM3_001418
SPBIO_001364
SPECTRUM2_001382
SPBIO_002523
PRESTWICK0_000312
1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine
FT-0630654
CHEMBL3195822
Q27163979
DTXSID00860646

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency15.84890.031637.5844354.8130AID504865
regulator of G-protein signaling 4Homo sapiens (human)Potency0.06700.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency20.54380.001310.157742.8575AID1259253; AID1259255; AID1259256
gemininHomo sapiens (human)Potency11.88560.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
b 844-39[no description available]low00diarylmethane
3-[(4-chlorophenyl)-phenylmethoxy]-8-methyl-8-azabicyclo[3.2.1]octane[no description available]low00diarylmethane
adiphenine[no description available]low00diarylmethane
3-(2'-aminobenzhydryloxy)tropane[no description available]low00diarylmethane
2,2-bis(4-glycidyloxyphenyl)propane[no description available]low00diarylmethane
benproperine[no description available]low00diarylmethane
cogentin[no description available]low00diarylmethane
bifemelane[no description available]low00diarylmethane
bisacodyl[no description available]low00diarylmethane
chlorcyclizine[no description available]low00diarylmethane
cifenline[no description available]low00diarylmethane
clidinium[no description available]low00diarylmethane
clofedanol[no description available]low00diarylmethane;
tertiary amino compound		antitussive
clofoctol[no description available]low00diarylmethane
cloperastine[no description available]low00diarylmethane
r 59022[no description available]low00diarylmethane
dichlorophen[no description available]low00bridged diphenyl fungicide;
diarylmethane
fendiline[no description available]low00diarylmethane
fluspirilene[no description available]low00diarylmethane
homochlorocyclizine[no description available]low00diarylmethane
isopropamide iodide[no description available]low00diarylmethane
lidoflazine[no description available]low00diarylmethane
lomerizine[no description available]low00diarylmethane
manidipine[no description available]low00diarylmethane
meclizine[no description available]low00diarylmethane
mepenzolate[no description available]low00diarylmethane
methadone[no description available]low00benzenes;
diarylmethane;
ketone;
tertiary amino compound
mitotane[no description available]low00diarylmethane
no 711[no description available]low00diarylmethane
oxatomide[no description available]low00benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
pipenzolate[no description available]low00diarylmethane
piperidolate[no description available]low00diarylmethane
proadifen[no description available]low00diarylmethane
propiverine[no description available]low00diarylmethane
aurin[no description available]low00diarylmethane
dpi 201-106[no description available]low00diarylmethane
terfenadine[no description available]low00diarylmethane
mepenzolate bromide[no description available]low00diarylmethane
chlorphenoxamine[no description available]low00diarylmethaneanticoronaviral agent
chlorfenethol[no description available]low00diarylmethane
diphenadione[no description available]low00beta-triketone;
diarylmethane
phenyltoloxamine[no description available]low00diarylmethane
n,n,n',n'-tetramethyl-4,4'-methylenedianiline[no description available]low00diarylmethane
diphenan[no description available]low00diarylmethane
diphenylmethane[no description available]low00diarylmethane
2,2'-methylenebis(4-methyl-6-tert-butylphenol)[no description available]low00diarylmethane
piperidolate hydrochloride[no description available]low00diarylmethane
benactyzine[no description available]low00diarylmethane
prenylamine[no description available]low00diarylmethane
isomethadone[no description available]low00diarylmethane
pipradrol[no description available]low00diarylmethane
normethadone[no description available]low00diarylmethane
captodiamine[no description available]low00diarylmethane
methadyl acetate[no description available]low00diarylmethane
benzomethamine[no description available]low00diarylmethane
chlorobenzilate[no description available]low00diarylmethane
dimenhydrinate[no description available]low00diarylmethane
poldine[no description available]low00diarylmethane
thiphenamil[no description available]low00diarylmethane
4-cumylphenol[no description available]low00diarylmethane
4,4'-bisphenol f[no description available]low00bisphenol;
diarylmethane		environmental food contaminant;
xenoestrogen
o,p'-ddt[no description available]low00diarylmethane
4,4'-methylene bis(2-methylaniline)[no description available]low00diarylmethane
dipipanone[no description available]low00diarylmethane
diphenamid[no description available]low00diarylmethane
paracymethadol[no description available]low00diarylmethane
bisphenol a-glycidyl methacrylate[no description available]low00diarylmethane
azacyclonol[no description available]low00diarylmethane
dimenoxadol[no description available]low00diarylmethane
amphenone b[no description available]low00diarylmethane
propinox[no description available]low00diarylmethane
embramine[no description available]low00diarylmethane
chlorophacinone[no description available]low00beta-triketone;
diarylmethane
aminopentamide[no description available]low00diarylmethane
octocrylene[no description available]low00diarylmethane
terodiline[no description available]low00diarylmethane
tofenacin[no description available]low00diarylmethane
pipoxolan[no description available]low00diarylmethane
penfluridol[no description available]low00diarylmethane
emepronium[no description available]low00diarylmethane
levomethadyl acetate hydrochloride[no description available]low00diarylmethane
flumecinol[no description available]low00diarylmethane
setastine[no description available]low00diarylmethane
progabide[no description available]low00diarylmethane
beclobrate[no description available]low00diarylmethane
cetirizine dihydrochloride[no description available]low00diarylmethane
niguldipine[no description available]low00diarylmethane
mandrax[no description available]low00diarylmethane
droprenylamine[no description available]low00diarylmethane
quifenadine[no description available]low00diarylmethane
carebastine[no description available]low00diarylmethane
lercanidipine[no description available]low00diarylmethane
diphenidol hydrochloride[no description available]low00diarylmethane
dioxadrol[no description available]low00diarylmethane
budipine[no description available]low00diarylmethane
epicainide[no description available]low00diarylmethane
butinoline[no description available]low00diarylmethane
denaverine[no description available]low00diarylmethane
lifarizine[no description available]low00diarylmethane
fenpiverinium[no description available]low00diarylmethane
2,2-methylenebis(4-chloro-3-methyl-isopropylphenol)[no description available]low00diarylmethane
amperozide[no description available]low00diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
2,2'-bisphenol f[no description available]low00diarylmethane
3-hydroxy-2,2-diphenylpropanoic acid[no description available]low00diarylmethane
1,1-Dichloro-2,2-bis(4-hydroxyphenyl)ethylene[no description available]low00diarylmethane
bisphenol f diglycidyl ether[no description available]low00aromatic ether;
diarylmethane;
epoxide
n-(4,4-diphenyl-3-butenyl)nipecotic acid[no description available]low00diarylmethane
methylene bis(methylanthranilate)[no description available]low00diarylmethane
tesmilifene[no description available]low00diarylmethane
pd 123177[no description available]low00diarylmethane
bw 373u86[no description available]low00diarylmethane
gilutensin hydrochloride[no description available]low00diarylmethane
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide[no description available]low00diarylmethane
ae0047[no description available]low00diarylmethane
lercanidipine hydrochloride[no description available]low00diarylmethane
cloperastine hydrochloride[no description available]low00diarylmethane
1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane[no description available]low00diarylmethane
2-[(4,6-dimethyl-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropanoic acid[no description available]low00diarylmethane
ci 966[no description available]low00diarylmethane
Difeterol[no description available]low00diarylmethane
1,1-bis(4-hydroxyphenyl)cyclohexane[no description available]low00diarylmethane
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene[no description available]low00diarylmethane
N-[2-(dimethylamino)ethyl]-2,2-diphenylacetamide[no description available]low00diarylmethane
propiverine hydrochloride[no description available]low00diarylmethane
gw 3965[no description available]low00diarylmethane
1,1-Bis(4-hydroxyphenyl)ethane[no description available]low00diarylmethane
uk 78282[no description available]low00diarylmethane
r 59949[no description available]low00diarylmethane
4-[1-(4-hydroxyphenyl)ethenyl]phenol[no description available]low00diarylmethane
5-[4-(diphenylmethyl)-1-piperazinyl]-2-(2-methoxyphenyl)-4-oxazolecarbonitrile[no description available]low00diarylmethane
flunarizine[no description available]low00diarylmethane
N-[4-[oxo-[(1-oxo-2,2-diphenylethyl)hydrazo]methyl]phenyl]propanamide[no description available]low00diarylmethane
[4-(diphenylmethyl)-1-piperazinyl]-[5-thiophen-2-yl-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinyl]methanone[no description available]low00diarylmethane
benztropine[no description available]low00diarylmethane
3-[[[(1-oxo-2,2-diphenylethyl)amino]-sulfanylidenemethyl]amino]benzoic acid[no description available]low00diarylmethane
3-bromo-5-[[4-[hydroxy(diphenyl)methyl]-1-piperidinyl]-oxomethyl]-2-pyranone[no description available]low00diarylmethane
2-(5-bromo-3-nitro-1,2,4-triazol-1-yl)-N-(diphenylmethyl)acetamide[no description available]low00diarylmethane
1,1-bis(4-chlorophenyl)-2-[(3-methoxyphenyl)methylamino]ethanol[no description available]low00diarylmethane
cinnarizine[no description available]low00diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
levocetirizine[no description available]low00diarylmethane
amn082[no description available]low00benzenes;
diamine;
diarylmethane;
secondary amino compound		metabotropic glutamate receptor agonist;
neuroprotective agent
N-[2-[tert-butyl(methyl)amino]ethyl]-N-methyl-2,2-diphenylacetamide[no description available]low00diarylmethane
N-(4-fluorophenyl)-4-[hydroxy(diphenyl)methyl]-1-piperidinecarbothioamide[no description available]low00diarylmethane
4-oxo-3-[(1-oxo-2,2-diphenylethyl)amino]-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester[no description available]low00diarylmethane
2,2-diphenylacetic acid (2,6-dimethylphenyl) ester[no description available]low00diarylmethane
1-ethyl-3-[(1-oxo-2,2-diphenylethyl)amino]thiourea[no description available]low00diarylmethane
2-(phenylmethyl)benzoic acid [2-[4-(difluoromethylthio)anilino]-2-oxoethyl] ester[no description available]low00diarylmethane
2-[2-[bis(4-methoxyphenyl)methylidene]hydrazinyl]benzoic acid[no description available]low00diarylmethane
N-[4-bromo-2-[[(2-hydrazinyl-2-oxoethyl)amino]-phenylmethyl]phenyl]-3-(4-morpholinyl)propanamide[no description available]low00diarylmethane
N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]-1-piperidinecarbothioamide[no description available]low00diarylmethane
4-[hydroxy(diphenyl)methyl]-N-(2-phenylethyl)-1-piperidinecarbothioamide[no description available]low00diarylmethane
3-(5-chloro-2-hydroxyphenyl)-3-phenyl-N-[(4-propan-2-yloxyphenyl)methyl]propanamide[no description available]low00diarylmethane
adrafinil[no description available]low00diarylmethane
zamifenacin[no description available]low00diarylmethane
2-(cyclohexylamino)-N-[(diphenylmethylene)amino]propanamide[no description available]low00diarylmethane
3-[[4-(diphenylmethyl)-1-piperazinyl]-oxomethyl]-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-12-one[no description available]low00diarylmethane
3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane[no description available]low00diarylmethane
flunarizine hydrochloride[no description available]low00diarylmethane
(2-amino-5-chlorophenyl)(phenyl)methanone oxime[no description available]low00diarylmethane
imidafenacin[no description available]low00diarylmethane
2-(3,3-diphenylpropylamino)acetamide[no description available]low00diarylmethane
cgk 733[no description available]low00diarylmethane
dexniguldipine[no description available]low00diarylmethane
lu 208075[no description available]low00diarylmethane
fesoterodine[no description available]low00diarylmethane
3-(diphenylmethylene)-1-[4-(4-phenyl-1-piperazinyl)butyl]pyrrolidine-2,5-dione[no description available]low00diarylmethane
pnu 200577[no description available]low00diarylmethane
gc 1 compound[no description available]low00diarylmethane
tas 301[no description available]low00diarylmethane
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol[no description available]low00diarylmethane
[4-(diphenylmethyl)-1-piperazinyl]-(5-methyl-4-nitro-3-isoxazolyl)methanone[no description available]low00diarylmethane
1-(1,4-dioxan-2-yl)-N-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-N-methylmethanamine[no description available]low00diarylmethane
1-[4-(3-chlorophenyl)-1-piperazinyl]-3-(diphenylmethyl)oxy-2-propanol[no description available]low00diarylmethane
(8R)-3-[3-[[2-(4-chlorophenoxy)-1-oxoethyl]amino]phenyl]-7-(1-oxo-3,3-diphenylpropyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-8-carboxamide[no description available]low00diarylmethane
3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-(3-methyl-1-piperidinyl)-1-propanone[no description available]low00diarylmethane
2-[[[4-[[(diphenylmethyl)amino]-oxomethyl]-1H-imidazol-5-yl]-oxomethyl]amino]acetic acid tert-butyl ester[no description available]low00diarylmethane;
tert-butyl ester
pf 04971729[no description available]low00diarylmethane
ML-210[no description available]low00C-nitro compound;
diarylmethane;
isoxazoles;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
tertiary carboxamide		antineoplastic agent;
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer;
prodrug
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Disease Models, Animal0low10
Fever, Zika0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]